Drug Profile

HS 20094

Alternative Names: HS-20094

Latest Information Update: 12 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Hansoh Pharmaceutical
Class Antihyperglycaemics; Obesity therapies
Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Obesity
Phase II Type 2 diabetes mellitus

Most Recent Events

02 Jun 2025 Regeneron in-licenses HS 20094 from Jiangsu Hansoh Pharmaceutical
11 Nov 2024 Phase-III clinical trials in Obesity (In volunteers) in China (SC) (NCT06839664)
09 Sep 2024 Adverse events and efficacy data from a phase-II trial in Type 2 diabetes mellitus presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD-2024),

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com